Yale University

Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.

TitleProphylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.
Publication TypeJournal Article
Year of Publication2002
AuthorsGoldie, Sue J., Jonathan E. Kaplan, Elena Losina, Milton C. Weinstein, David A. Paltiel, George R. Seage, Donald E. Craven, April D. Kimmel, Hong Zhang, Calvin J. Cohen, and Kenneth A. Freedberg
JournalArchives of internal medicine
Volume162
Issue8
Pagination921-8
Date Published2002 Apr 22
ISSN0003-9926
KeywordsAIDS-Related Opportunistic Infections, Anti-Infective Agents, Antiprotozoal Agents, Atovaquone, CD4 Lymphocyte Count, Cost-Benefit Analysis, Dapsone, Drug Costs, Humans, Life Expectancy, Models, Theoretical, Naphthoquinones, Pentamidine, Pneumonia, Pneumocystis, Practice Guidelines as Topic, Quality-Adjusted Life Years
AbstractHuman immunodeficiency virus (HIV)-infected patients receiving highly active antiretroviral therapy (HAART) have experienced a dramatic decrease in Pneumocystis carinii pneumonia (PCP), necessitating reassessment of clinical guidelines for prophylaxis.
DOI10.1111/j.1524-4733.2010.00763.x
Alternate JournalArch. Intern. Med.

External Links